News for Emmaus Life Sciences, Inc. (EMMA)

PR NewswireTORRANCE, Calif., Nov. 19, 2024 TORRANCE, Calif., Nov. 19, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage bio

Crinetics pharmaceuticals exec sells over $785k in stock

Emmaus Life Sciences appoints new board member

The Dow Jones index closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the com...

The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

The global sickle cell disease treatment market size is anticipated to grow from USD 2 billion to USD 12.38 billion in 10 years. The market will experience...

TORRANCE, Calif., Feb. 2, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment, today announced that it has received marketing authorization from the Puerto...

Prominence of Personalized Medicine Approaches as a Notable Trend in the Hemoglobinopathy Market...

Item1.01 Entry into a Material Definitive Agreement On December 15, 2023, Emmaus Life Sciences, Inc. entered into an Exchange Agreement with Wei Peu Zen and Seah Lim,...

The global sickle cell disease treatment market is growing at a CAGR of 19.1% from 2022 to 2030....

The global malaria treatment market revenue to reach $24.48 Billion by 2030....

The global malaria and sickle cell disease treatment market is growing at a CAGR of 26.5% from 2022 to 2030....

As per the report by Fortune Business Insights, the global Sickle Cell Disease Treatment Market size is projected to reach USD 8.75 billion in 2029, at a...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

Read Ocumetics Technology (OTCMKTS:MYND) Trading Down 15.2% at ETF Daily News

Read Ocumetics Technology (OTCMKTS:MYND) Stock Price Down 15.2% at ETF Daily News

Read Vertex Pharmaceuticals (NASDAQ:VRTX) vs. Emmaus Life Sciences (OTCMKTS:EMMA) Head to Head Contrast at ETF Daily News

Read Ocumetics Technology (OTCMKTS:MYND) Stock Price Down 15.2% at ETF Daily News

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...